↓ Skip to main content

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Overview of attention for article published in Breast Cancer Research, April 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy
1 policy source
twitter
2 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
Published in
Breast Cancer Research, April 2015
DOI 10.1186/s13058-015-0568-1
Pubmed ID
Authors

Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U Buzdar, Pierre Fumoleau, William Gradishar, Miguel Martin, Beverly Moy, Martine Piccart-Gebhart, Kathleen I Pritchard, Deborah Lindquist, Erica Rappold, Dianne M Finkelstein, Paul E Goss

Abstract

Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Disease-free survival (DFS) was 75% after 5 and 61% after 10 years, respectively. Patients with HER2+ hormone receptor positive (HR+ (hormone receptor positive); ER+ (estrogen receptor positive) or PR+ (progesterone receptor positive)) disease had a significantly better DFS than patients with HER2 + HR- (ER-/PR-) disease (hazard ratio 0.72, P = 0.02). This difference was explainable by a significantly higher hazard of recurrence in years 1-5 in HER2 + HR- compared to HER2 + HR+ patients, with a mean risk of recurrence of 9%/year for HR- versus 5%/years in HR+ patients (hazard ratio 0.59, P = 0.002 for years 1-5). The high early risk of recurrence of HER2 + HR- patients declined sharply over time, so that it was similar to that seen in HER2 + HR+ patients in years 6-10 (hazard ratio 0.97, P = 0.92 for years 6-10). Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2 + HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2 + HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Colombia 1 1%
Denmark 1 1%
Unknown 72 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 21%
Other 14 19%
Student > Bachelor 8 11%
Student > Master 7 9%
Student > Ph. D. Student 6 8%
Other 10 13%
Unknown 14 19%
Readers by discipline Count As %
Medicine and Dentistry 22 29%
Biochemistry, Genetics and Molecular Biology 11 15%
Agricultural and Biological Sciences 8 11%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Nursing and Health Professions 3 4%
Other 11 15%
Unknown 16 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2018.
All research outputs
#5,882,369
of 22,799,071 outputs
Outputs from Breast Cancer Research
#706
of 1,899 outputs
Outputs of similar age
#62,124
of 237,938 outputs
Outputs of similar age from Breast Cancer Research
#17
of 43 outputs
Altmetric has tracked 22,799,071 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,899 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,938 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.